Pimavanserin

Independent reference data for Pimavanserin (CAS 706779-91-1), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Pimavanserin is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.Pimavanserin is an atypical antipsychotic that received FDA approval in the U.S. in 2016 for hallucinations and delusions that accompany Parkinson disease psychosis (PDP). It is the first and only FDA-approved medication for PDP. It had initially received Breakthrough Therapy status from the FDA in 2014. In the phase III clinical trial that paved the way for FDA approval, patients receiving pimavanserin demonstrated significant improvement in the frequency and/or severity of hallucinations and/or delusions without

Synonyms and trade names

Pimavanserin; 706779-91-1; ACP-103; pimavanserina; pimavanserine; JZ963P0DIK; CHEBI:133017; DTXSID90990906; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide; ACP 103; N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide; 1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-{[4-(2-methylpropoxy)phenyl]methyl}urea; pimavanserinum; 1-((4-fluorophenyl)methyl)-1-(1-methylpiperidin-4-yl)-3-((4-(2-methylpropoxy)phenyl)methyl)urea; RefChem:59074

What the public record says

Pimavanserin · CAS 706779-91-1 · C25H34FN3O2. UNII JZ963P0DIK. Boiling Point: 604.2±55.0; Melting Point: 117-119; Dissociation Constants: 13.52±0.46.

Source: PubChem / Wikidata; the batch COA governs where values differ.